Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Carcinoma, Renal Cell
  • Clinical Trials as Topic
  • Kidney Neoplasms

abstract

  • Treatment with novel agents during a clinical trial is indicated for patients with metastatic RCC after progression to cytokine treatment. Three prognostic factors for predicting survival were used to categorize patients into risk groups. These risk categories can be used in clinical trial design and interpretation.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.06.132

PubMed ID

  • 14752067

Additional Document Info

start page

  • 454

end page

  • 63

volume

  • 22

number

  • 3